An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Trial details
- Registry ID
- NCT06927999
- Drugs studied
- 0.5 mg epinephrine, 1 mg epinephrine
TrialRedline tracks 3 clinical trials sponsored by ARS Pharmaceuticals, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous UrticariaNCT06927999 | 0.5 mg epinephrine, 1 mg epinephrine | Recruiting | 2027-06Estimated |
| Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria FlaresNCT05496465 | ARS-1 | Completed | 2024-02-29Actual |
| Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaNCT05363670 | ARS-1 1 mg, ARS-1 2mg, Albuterol MDI | Completed | 2024-02-02Actual |
Names as written in the registry records.
NCT06927999 · ARS Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive. After: Measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch.
NCT06927999 · ARS Pharmaceuticals, Inc.
Before: Jun 2026. After: Jun 2027.
NCT05363670 · ARS Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Effect of ARS-1 versus Albuterol and placebo. After: Measure: Effect of ARS-1 Versus Albuterol and Placebo.
NCT05496465 · ARS Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score. After: Measure: Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive Score.
Before: 24 participants (actual). After: 21 participants (actual).